IDEAYA Biosciences, Inc.’s $57.5 Million Initial Public Offering


Davis Polk advised the underwriters in connection with an initial public offering of 5,750,000 shares of common stock of IDEAYA Biosciences, Inc. at $10.00 per share (which includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares), for total gross proceeds of $57.5 million.

The common stock is listed on the Nasdaq Global Select Market under the symbol “IDYA.”

J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Jefferies LLC acted as underwriters in the deal.

Based in South San Francisco, California, IDEAYA is a clinical stage oncology-focused precision medicine company developing targeted therapeutics for patients selected using molecular diagnostics across multiple oncology indications.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture) and associates Beth LeBow and Jonathan Bye. The tax team included partner Rachel D. Kleinberg. The intellectual property and technology team included associates Daniel F. Forester, Michael V. Policastro and S. Dream Montgomery. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: Jonathan Bye – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Daniel Forester – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Beth LeBow – Davis Polk & Wardwell; S. Dream Montgomery – Davis Polk & Wardwell; Michael Policastro – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Citigroup Global Markets Ltd; J.P. Morgan Securities LLC; Jefferies;

Author: Ambrogio Visconti